Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Mabwell logo — Explore Life, Benefit Health

Mabwell

Explore Life, Benefit Health

Founded 2017 China Shanghai, China 122 employees IPO Total: $825.50M Biopharma, Biotechnology +1

General Information

Company Name Mabwell
Founded Year 2017
Location China Shanghai, China
Employees 122
Industries Biopharma, Biotechnology, Life Sciences
Funding Stage IPO
Business Model B2B, B2C, B2D
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Mabwell. To contact Mabwell, visit mabwell.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Mabwell compare?

A PDF of Mabwell and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Mabwell soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Mabwell

Mabwell (688062.SH) is an emerging player in the Biopharma and Biotechnology arena, founded in 2017 and headquartered in China. With its slogan, "Explore Life, Benefit Health," the company's mission to advance global medical needs is evident through its robust capabilities in research and development, manufacturing, and commercialization of biopharmaceutical products.

Mabwell has positioned itself as a leader in delivering innovative and accessible medical therapies by harnessing the full industrial chain. Its vision, "Innovation, from ideas to reality," underpins the company's strategic direction and commitment to transforming concepts into tangible health solutions.

The company garnered significant attention in the investment community with a substantial $547.00M IPO investment on 01 January 2022. This financial backing underscores investor confidence in Mabwell's potential to drive progress within the Life Sciences sector and shape future healthcare through novel therapeutic developments.

Business keywords: Biopharmaceuticals, R&D, Commercialization, Innovative Medicines, Monoclonal Antibodies, Recombinant Proteins, Oncology, Autoimmune Diseases, Anti-infection Therapy, Ophthalmic Diseases, Clinical Trials, Therapeutic Macromolecules, Age-related Diseases, Antibody-drug Conjugates (ADC)

Services & Products

Research and Development
Pharmaceutical Manufacturing
Drug Commercialization
Biotech Innovation

Target Customers

Patients with Unmet Clinical Needs Healthcare Providers Medical Researchers Pharmaceutical Partners

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
IPO $547.00M -
01 Jan 2022
Series A $278.50M 8
Loyal Valley Capital Oriental Fortune Capital Shiyu Capital
Loyal Valley Capital, Oriental Fortune Capital +6
01 Apr 2020

Mabwell Alternatives & Competitors

View All Alternatives
Mabwell vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
Compare Mabwell vs Antharis Therapeutics, Inc.
Mabwell vs
Biocon
Biocon India

Transforming Healthcare. Transforming Lives.

IPO
11576 employees
Biopharma, Biotechnology
Compare Mabwell vs Biocon
Mabwell vs
Pheon Therapeutics
Pheon Therapeutics United Kingdom

Pheon is an Antibody-Drug Conjugate specialist developing next generation ADCs for a range of hard-t...

Series B
26 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Mabwell

Explore Life, Benefit Health
Mabwell was founded in 2017.
Mabwell is headquartered in Shanghai, China.
Mabwell operates in Biopharma, Biotechnology and Life Sciences. Its work centres on Biopharmaceuticals, R&D, Commercialization and Innovative Medicines. Its customers include Patients with Unmet Clinical Needs, Healthcare Providers and Medical Researchers.
Mabwell has a B2B, B2C and B2D business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Mabwell has approximately 122 employees.
Mabwell has completed 2 funding rounds, raising a total of $825.50M. The latest funding stage is IPO.
Mabwell offers: Research and Development, Pharmaceutical Manufacturing, Drug Commercialization, Biotech Innovation.
Top alternatives and competitors to Mabwell include Antharis Therapeutics, Inc., Biocon, Pheon Therapeutics, Arcus Biosciences, ADC Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Mabwell and Antharis Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Mabwell, https://bouncewatch.com/company/mabwell-biotech, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes